Our NAV-005 antagonist binds the immunosuppressive HIO-1 factor and blocks its ability to suppress mAb, TCE and ADC ...
A new malaria vaccine achieves an unparalleled 89% efficacy by targeting late-liver-stage antigens, unlocking new horizons in the fight against global disease. Study: Safety and Efficacy of ...
Tokyo Medical and Dental University (TMDU) researchers have discovered that patients with 18q deletion syndrome can experience both cellular and humoral immunodeficiency Tokyo, Japan – Chromosome 18q ...
Researchers have revealed a novel association between chromosome 18q deletion syndrome and late-onset combined immunodeficiency (LOCID). Their finding challenges the previously held notion that 18q ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results